arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Rani Therapeutics Holdings, Inc.

RANI

$0.79 ▲ +0.01 (+0.65%) at close

6 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

Rani Therapeutics Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —

Dividend Yield —

Revenue Growth 58.9%

Op. Margin —

ROIC -91.7% ↗

FCF / Share —

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.63M

↑ +58.9% —

Net Income Profit after all expenses

$-29.67M

↑ +1.1% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	58.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+636%)	—	—	N/M	488.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6001%)	—
EPS Growth YoY (%)	57.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	21.1% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-3.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-197.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	1.1% Caution ↑ Caution Improving Year-over-year change in net income	11.6% Fair ↑ Fair Improving Year-over-year change in net income	-11.1% Weak ↑ Weak Improving Year-over-year change in net income	-267.2% Weak Weak Year-over-year change in net income	50.1% Excellent Excellent Year-over-year change in net income	—
Revenue CAGR 3Y (%)	—	-27.7% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	28.7% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Effective Tax Rate (%) (%)	—	—	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	—	—	—	—	-306.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2655%)	—
FCF / Net Income (x)	0.63x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.54x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	1.57x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	3.93x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-91.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-156.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-154.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-95.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-108.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	14.9% Good Good Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-65.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-145.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-114.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-20.8% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	-89.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-699%)	—	-264.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1860%)	-83.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-653%)	-17.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-217%)	14.7% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Debt to Equity (x)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	12.55x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1992%)	2.33x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+289%)	0.81x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+36%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	-0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-104%)
Interest Coverage (x)	-13.25x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-10.59x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-13.00x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-59.24x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-110.73x Weak Weak Operating income divided by interest expense Optimal: > 5x	-133.42x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-18.62M	$21.24M	$24.14M	$2.99M	$-117.45M	$-70.65M
Debt / EBITDA (x)	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.48x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.46x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.48x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.15x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x

📊 What does each share earn? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.45	$-1.05	$-1.33	$-1.28	$-0.43	—
Basic Weighted Avg Shares (shares)	66,138	28,476	25,505	23,817	19,534	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$40.65M	$9.85M	$42.86M	$96.11M	$116.95M	$69.64M
LT Debt (USD)	$0.00	$25.00M	$30.00M	$30.00M	$0.00	$2.41M
Total Equity (USD)	$33.01M	$1.99M	$12.87M	$36.85M	$47.41M	$-113.34M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$1.63M	$1.03M	—	$0.00	$2.72M	$462.00K
Depreciation Expense (USD)	$900.00K	$1.00M	$800.00K	$500.00K	$500.00K	$589.00K
Net Income, GAAP (USD)	$-29.67M	$-30.02M	$-33.97M	$-30.59M	$-8.33M	$-16.70M
Operating Cash Flow (USD)	$-18.71M	$-35.50M	$-51.24M	$-46.52M	$-32.24M	$-14.96M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters

Rani Therapeutics Holdings, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RANI with peers